Sands Capital Life Sciences Pulse Fund Ii, L.P. bought IKT once, on Nov 21, 2025
10% owner at Inhibikase Therapeutics, Inc.
SEC CIK 0001875620 · Filings on SEC.gov ↗
Sands Capital Life Sciences Pulse Fund Ii, L.P.'s record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
1 filing since Nov 2025, newest first
About Sands Capital Life Sciences Pulse Fund Ii, L.P.
Sands Capital Life Sciences Pulse Fund II, L.P. is a venture capital fund managed by Sands Capital Ventures, LLC, part of the Sands Capital group, focusing on investments in private therapeutics, diagnostics, and life sciences tools to transform disease definition, diagnosis, and treatment.( Raised in 2021 with $560 million, it follows the 2018 Pulse I fund, bringing total Pulse Strategy assets under management to over $950 million at the time, and has participated in investments across 20 businesses since inception.( The fund recently traded as a 10% corporate insider in Inhibikase Therapeutics, Inc. (IKT).
Sands Capital, founded in 1992 and based in Arlington, Virginia, is an independent, staff-owned investment firm managing over $80 billion in public and private investments as of mid-2021, with more than $9 billion committed to global life sciences and healthcare.( The Life Sciences Pulse team includes dedicated partners and analysts like Managing Partner Stephen Zachary, leveraging the firm's global platform for long-term growth investments in innovative businesses.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.